I recently noted, both Oxford BioMedica and Genzyme had stopped recruiting for their respective gene therapy clinical trials this summer. Oxford announced the reason for its stoppage (a trace of contaminant found in a third-party supplied component), but no word from Genzyme (and no response to my attempts to find out).

Well, Oxford announced that it had resumed its clinical trial after receiving clearances from both the FDA and the French regulatory agency, ANSM.

For the story behind the story, please take a look at my write up ^[1].

And, Genzyme recently provided the answer for why it had stopped recruitment.